{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:13:20Z","timestamp":1777860800804,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prophylactic medications are commonly used to prevent tuberculosis and opportunistic infections in people living with HIV (PLWH) who are on first-line antiretroviral therapy (ART). However, their cumulative influence on cluster of differentiation 4 (CD4) responses is still a subject of ongoing investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted utilizing secondary data derived from medical records of 500 people living with HIV (\u2265\u200915 years) who initiated first-line ART at Jinka General Hospital in Ari Zone, South Ethiopia, between September 2019 and January 2025. CD4 response was defined as an increase of \u2265\u200950 cells\/\u00b5L from baseline to the most recent measurement. The most recent CD4 measurement taken up to January 2025 was used for analysis. The primary outcome measure was a binary variable for CD4 response, defined as an increase of \u2265\u200950 cells\/\u00b5L from baseline to end-line counts. Multivariable binary logistic regression was used to assess independent and interaction effects of prophylactic therapies on CD4 response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 500 participants, 50.2% demonstrated an improvement in CD4 count. Use of cotrimoxazole preventive therapy (CPT), isoniazid preventive therapy (IPT), and opportunistic infection (OI) medications was each independently associated with higher odds of CD4 improvement. However, interaction analysis showed that the CPT-OI combination and the triple CPT-IPT-OI regimen showed a statistically significant interaction suggesting a possible synergistic association with CD4 recovery beyond their individual additive effects. Predicted probabilities of CD4 improvement increased progressively with dual and triple prophylactic combinations compared with no prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combined use of prophylactic medications was significantly associated with CD4 recovery in people living with HIV on first-line ART. These findings emphasize the importance of integrated preventative strategies, particularly in resource-limited settings, and highlight the need for adherence support among individuals with limited formal education and those living in rural areas. The study\u2019s generalizability is limited, however, due to its single-center retrospective design and the use of a broad category for \u201cOI prophylaxis\u201d without specifying individual drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-026-00873-6","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:55:14Z","timestamp":1774252514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cumulative effect of cotrimoxazole, isoniazid and opportunistic infection prophylaxis on CD4 response among people living with HIV on first-line ART in Ari Zone, Southern Ethiopia"],"prefix":"10.1186","volume":"23","author":[{"given":"Sitotaw","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tegenu","family":"Tento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurhussen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"873_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-024-19268-1","volume":"24","author":"BZ Woldegeorgis","year":"2024","unstructured":"Woldegeorgis BZ, Asgedom YS, Habte A, Kassie GA, Badacho AS. Highly active antiretroviral therapy is necessary but not sufficient. A systematic review and meta-analysis of mortality incidence rates and predictors among HIV-infected adults receiving treatment in Ethiopia, a surrogate study for resource-poor settings. BMC Public Health. 2024;24(1):1\u201319.","journal-title":"BMC Public Health"},{"issue":"11","key":"873_CR2","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","volume":"3","author":"S Kanters","year":"2016","unstructured":"Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510-20.","journal-title":"Lancet HIV."},{"issue":"11","key":"873_CR3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.7326\/0003-4819-120-11-199406010-00006","volume":"120","author":"JE Gallant","year":"1994","unstructured":"Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994;120(11):932\u201344.","journal-title":"Ann Intern Med"},{"issue":"9443","key":"873_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(04)17225-5","volume":"364","author":"J Mermin","year":"2004","unstructured":"Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364(9443):1428\u201334.","journal-title":"Lancet"},{"key":"873_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9741157","author":"K Nigussie","year":"2024","unstructured":"Nigussie K, Gebeye E, Kifle ZD, Tadesse TY, Birarra MK. Impact of isoniazid preventive therapy on tuberculosis incidence and predictors of tuberculosis among people living with hiv\/aids at debre tabor general hospital, Northwest Ethiopia. Tuberc Res Treat. 2024. https:\/\/doi.org\/10.1155\/2024\/9741157.","journal-title":"Tuberc Res Treat"},{"issue":"4","key":"873_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/01.qai.0000225729.79610.b7","volume":"42","author":"CB Holmes","year":"2006","unstructured":"Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: Implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42(4):464\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"873_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJM200103293441307","volume":"344","author":"SC Piscitelli","year":"2001","unstructured":"Piscitelli SC, Gallicano KD. Interactions among Drugs for HIV and opportunistic infections. N Engl J Med. 2001;344(13):984\u201396.","journal-title":"N Engl J Med"},{"key":"873_CR8","unstructured":"Edith TUMWEBAZE. the effect of age, gender and location of residence on Cd4 counts response to Arv therapy in patients who attend Nyagatare hospital in Vct Service. 2010; (January 2012)."},{"key":"873_CR9","unstructured":"NIH, Laboratory Testing. Plasma HIV-1 RNA (Viral Load) and CD4 count monitoring [cited 2025 Jul 1]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/plasma-hiv-1-rna-cd4-monitoring"},{"issue":"19","key":"873_CR10","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJM200005113421907","volume":"342","author":"J Oseph","year":"2000","unstructured":"Oseph J, Ovacs AK, Asur M. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med. 2000;342(19):1416\u201329.","journal-title":"N Engl J Med"},{"issue":"7","key":"873_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/hiv.12354","volume":"17","author":"J Collazos","year":"2016","unstructured":"Collazos J, Valle-Garay E, Carton JA, Montes AH, Suarez-Zarracina T, De la Fuente B, et al. Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy. HIV Med. 2016;17(7):532\u201341. https:\/\/doi.org\/10.1111\/hiv.12354.","journal-title":"HIV Med"},{"issue":"5","key":"873_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5582\/bst.2015.01107","volume":"9","author":"F Zhang","year":"2015","unstructured":"Zhang F, Sun M, Sun J, Guan L, Wang J, Lu H. The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China. Biosci Trends. 2015;9(5):335\u201341.","journal-title":"Biosci Trends"},{"issue":"12","key":"873_CR13","doi-asserted-by":"publisher","first-page":"e0226293","DOI":"10.1371\/journal.pone.0226293","volume":"14","author":"AA Desta","year":"2019","unstructured":"Desta AA, Woldearegay TW, Berhe AA, Futwi N, Gebru GG, Godefay H. Immunological recovery, failure and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on antiretroviral therapy in Northern Ethiopia: A retrospective cross sectional study. PLoS One. 2019;14(12):e0226293.","journal-title":"PLoS One"},{"issue":"5","key":"873_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217742","volume":"14","author":"T Kufa","year":"2019","unstructured":"Kufa T, Shubber Z, MacLeod W, Takuva S, Carmona S, Bor J, et al. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data. PLoS One. 2019;14(5): e0217742.","journal-title":"PLoS One"},{"issue":"2","key":"873_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4040\/jkan.2013.43.2.154","volume":"43","author":"HA Park","year":"2013","unstructured":"Park HA. An introduction to logistic regression: from basic concepts to interpretation with particular attention to nursing domain. J Korean Acad Nurs. 2013;43(2):154\u201364.","journal-title":"J Korean Acad Nurs"},{"issue":"2","key":"873_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.11613\/BM.2013.018","volume":"23","author":"ML Mchugh","year":"2013","unstructured":"Mchugh ML. The Chi-square test of independence lessons in biostatistics. Biochem Med (Zagreb). 2013;23(2):143\u20139. https:\/\/doi.org\/10.11613\/BM.2013.018.","journal-title":"Biochem Med (Zagreb)"},{"issue":"1989","key":"873_CR17","first-page":"1","volume":"2","author":"PD Allison","year":"2014","unstructured":"Allison PD. Measures of fit for logistic regression (Paper 1485\u20132014). SAS Glob Forum. 2014;2(1989):1\u201313.","journal-title":"SAS Glob Forum"},{"key":"873_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/jotm\/5989447","author":"AA Bekele","year":"2025","unstructured":"Bekele AA, Tegegne AS, Muhie NS. Determinants associated with CD4 cell count and disclosure status among first-line antiretroviral therapy patients treated at Felege Hiwot Comprehensive Specialized Hospital, Ethiopia. J Trop Med. 2025. https:\/\/doi.org\/10.1155\/jotm\/5989447.","journal-title":"J Trop Med"},{"key":"873_CR19","doi-asserted-by":"crossref","unstructured":"Guigon A, Coulon P, Pezzi L, Regueme A, Debuysschere C, Lazrek M et al. Evaluation of a fully automated assay for detection of antidengue IgM antibodies in a nonendemic area. Das B, editor. J Trop Med. 2025; 2025 (1).","DOI":"10.1155\/jotm\/4163150"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00873-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:02:49Z","timestamp":1777514569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12981-026-00873-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00873-6","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A waiver of informed consent was granted by the Jinka General Hospital ethical review board because the study used retrospective chart data and involved no direct contact with participants. The research protocol was also approved by the Jinka University research and ethics committee, with reference number JKU\/RPED\/193\/17. All procedures involving human participants in this study were carried out in accordance with the institutional and national research committee\u2019s ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}